Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is well positioned for future growth due to its strong portfolio of key products in the neuroscience, cardiometabolic, cancer, and immunology areas. The company's strategic focus on diversification and expansion into international markets is expected to result in strong revenue growth in the coming years. With impressive prescription trends and increasing market share, Lilly's 2026, 2027, and 2028 sales and earnings estimates outpace consensus expectations. The launch of Foundayo and the GLP-1 Bridge program for Medicare, along with strong performance in ex-US markets, further support a positive outlook for the company. Additionally, Lilly's focus on diversity, equity, and inclusion in clinical trials is a key factor in its long-term success and mitigates regulatory risks.

Bears say

Eli Lilly is a market leader in neuroscience, cardiometabolic, and immunology, with a diverse portfolio of key products. However, steep pricing pressures, underwhelming TRx growth in key products, and increased competition in the obesity landscape pose significant risks to the company's success. The company has shown strong revenue growth and a solid 2Q performance, but questions around GLP-1 demand and pricing remain. With a broad ex-CVM pipeline and a potential for a sustainable pricing model, the company's stock may have further upside potential, but it should be closely monitored due to potential headwinds.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,302.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,302.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.